This article is more than 5 years old. Information may no longer be current.

Combination therapy improved PFS in relapsed ovarian cancer

Add topic to email alerts

Receive an email when new articles are posted on

Please provide your email address to receive an email when new articles are posted on .

Subscribe

Added to email alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

You've successfully added to your alerts. You will receive an email when new content is published.

Click Here to Manage Email Alerts

Back to Healio

We were unable to process your request. Please try again later. If you continue to have this issue please contact customerservice@slackinc.com.

Back to Healio

33rd Congress of the European Society for Medical Oncology

Combination trabectedin and pegylated liposomal doxorubicin improved PFS for patients with relapsed ovarian cancer in a study presented at the 33rd Congress of the European Society for Medical Oncology in Stockholm.

Bradley J. Monk, MD, professor in the department of obstetrics and gynecology at the University of California Irvine Medical Center, presented results of the multicenter phase-3 study that compared the safety and efficacy of trabectedin (Yondelis; Zeltia, Johnson and Johnson) plus pegylated liposomal doxorubicin with pegylated liposomal doxorubicin alone.

The study included 672 patients with a median age of 57 years. The patients were randomly assigned to pegylated liposomal doxorubicin 30 mg/m² over 60 to 90 minutes with trabectedin 1.1 mg/m² over three hours every three weeks or pegylated liposomal doxorubicin 50 mg/m2 every four weeks.

Median length of PFS was 7.3 months among women assigned to combination, compared to 5.8 months for those assigned to pegylated liposomal doxorubicin alone. Patients assigned to combination therapy who relapsed more than six-months following first-line therapy had a median PFS of 9.2 months, compared with those assigned to pegylated liposomal doxorubicin alone whose median PFS was 7.5 months.

For more information:

• Monk BJ, Herzog TJ, Kaye S, et al. #LBA4. A randomized phase-3 study of trabectedin with pegylated liposomal doxorubicin vs. PLD in relapsed, recurrent ovarian cancer. Presented at: 33rd Congress of the European Society for Medical Oncology; Sept. 12-16, 2008; Stockholm.